XLO Xilio Therapeutics Inc

Price (delayed)

$8.94

Market cap

$58.83M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.64

Enterprise value

-$72.73M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 40
Highlights
Xilio Therapeutics's EPS has soared by 94% YoY and by 75% from the previous quarter
XLO's quick ratio has soared by 81% YoY and by 19% QoQ

Key stats

What are the main financial stats of XLO

XLO stock price

How has the Xilio Therapeutics stock price performed over time
Intraday
-1.11%
1 week
-0.45%
1 month
-3.14%
1 year
-17.3%
YTD
-0.22%
QTD
-6.68%

Financial performance

How have Xilio Therapeutics's revenue and profit performed over time
Revenue
$64.09M
Gross profit
$64.09M
Operating income
-$31.37M
Net income
-$21.83M
Gross margin
100%
Net margin
-34.1%
Xilio Therapeutics's net margin has soared by 91% YoY and by 42% from the previous quarter
The operating margin has surged by 87% year-on-year and by 38% since the previous quarter
Xilio Therapeutics's net income has soared by 61% YoY and by 30% from the previous quarter
XLO's operating income is up by 45% year-on-year and by 26% since the previous quarter

Price vs fundamentals

How does XLO's price correlate with its fundamentals

Growth

What is Xilio Therapeutics's growth rate over time

Valuation

What is Xilio Therapeutics stock price valuation
P/E
N/A
P/B
0.74
P/S
2.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.13
Xilio Therapeutics's EPS has soared by 94% YoY and by 75% from the previous quarter
XLO's price to book (P/B) is 50% lower than its 5-year quarterly average of 1.5
Xilio Therapeutics's revenue has increased by 20% QoQ
The stock's price to sales (P/S) is 2.1% less than its last 4 quarters average of 2.8

Efficiency

How efficient is Xilio Therapeutics business performance
Xilio Therapeutics's ROS has soared by 91% YoY and by 42% from the previous quarter
The return on equity has surged by 87% year-on-year and by 57% since the previous quarter
Xilio Therapeutics's return on assets has surged by 75% YoY and by 33% QoQ

Dividends

What is XLO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XLO.

Financial health

How did Xilio Therapeutics financials performed over time
The total assets is 88% higher than the total liabilities
XLO's current ratio has soared by 83% YoY and by 18% from the previous quarter
XLO's quick ratio has soared by 81% YoY and by 19% QoQ
Xilio Therapeutics's debt is 91% less than its equity
The company's debt to equity has shrunk by 92% YoY
Xilio Therapeutics's debt has decreased by 17% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.